ATH434 improves daily function and reduces brain iron in patients with multiple system atrophy, a rare, fatal ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ongoing ...

Ionis Pharmaceuticals Inc. (($IONS)) announced an update on their ongoing clinical study. Ionis Pharmaceuticals Inc. is conducting a Phase 1 study ...

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ...

Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label ...

Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...

PHILADELPHIA — The experimental vaccine UB-312 shows early promise in Parkinson's disease (PD) and multiple system atrophy (MSA), results of a phase 1b study suggest. "UB-312 immunization in ...

Alterity reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy. The trial enrolled 77 adults with early-stage MSA across 23 sites in six ...